Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Fires Warning Letter To Sun Pharma; Says Corrections At Cranbury Site Inadequate

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Sun Pharmaceuticals - India's largest company by market capitalization - has been issued a warning letter by U.S. FDA for significant violations of good manufacturing practices at its Cranbury-based manufacturing site

You may also be interested in...

Ranbaxy Shuffles Its CEO Again, Atul Sobti Steps Down As Daiichi Sankyo Appoints New Leader

MUMBAI - In a span of less than 15 months, Ranbaxy - now part of Japanese pharma Daiichi Sankyo - will see a second changing of the guard, as chief executive Atul Sobti steps down and hands over the reigns to Arun Sawhney, presently serving as president of Ranbaxy's global pharmaceutical business. Sawhney's promotion to managing director is effective Aug. 20

After U.S. FDA Action, Investors Take Caraco To Court Alleging Violation Of Securities Laws

MUMBAI - A group of shareholders of U.S.-based generic drug maker Caraco Pharmaceutical has taken the company to court alleging that it violated securities laws by "recklessly disregarding May 29, 2008 and June 25, 2009 that their public statements concerning Caraco's business, operations and prospects were materially false and misleading." One of India's top generic drug makers, Sun Pharma, owns a majority 76 percent equity stake in Caraco

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts